CHIH-HSIN YANGANN-LII CHENG2020-05-262020-05-2619960028-4793https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029800243&doi=10.1056%2fNEJM199611073351911&partnerID=40&md5=2d79fb21c72cb6c641bcef0f3b8457dahttps://scholars.lib.ntu.edu.tw/handle/123456789/495167[SDGs]SDG2[SDGs]SDG3polyprenoic acid; retinol; cancer adjuvant therapy; cancer inhibition; clinical article; clinical trial; controlled clinical trial; controlled study; drug efficacy; human; human cell; human tissue; letter; liver carcinogenesis; liver cell carcinoma; priority journal; recurrence risk; retinol deficiency; survival rate; treatment outcome; Antineoplastic Agents; Carcinoma, Hepatocellular; Data Interpretation, Statistical; Diagnosis, Differential; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Research Design; Tretinoinletter10.1056/NEJM19961107335191189270812-s2.0-0029800243